Changes in effectiveness and safety in patients with Lennox–Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open‐label extension study
Epilepsia Open · 2026
DOI: 10.1002/epi4.70320 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia Open, 2026. Verfasst von Rima Nabbout und 14 weiteren Autor:innen. Beteiligte Einrichtung: Necker Enfants Malades Hospital, APHP, Member of the European Reference Network (ERN) EpiCARE, Reference Centre for Rare Epilepsies, Paris, France. Hauptthemen laut MEDLINE: Fenfluramine, Lennox Gastaut Syndrome, Anticonvulsants, Seizures. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In the phase 3 randomized controlled trial (RCT; NCT03355209) of fenfluramine in Lennox–Gastaut syndrome (LGS), patients in fenfluramine treatment groups (0.2 mg/kg/day, 0.7 mg/kg/day) experienced greater reduction from baseline in frequency of seizures associated with a fall versus placebo, which was sustained in the open‐label extension (OLE) study (NCT03355209). In this post hoc analysis, trajectories of fenfluramine effectiveness and safety, along with dose changes over time, are described for patients with LGS randomized to placebo in RCT who switched to fenfluramine in OLE (PBO‐FFA) and those who received fenfluramine in both RCT/OLE (FFA‐FFA). Among patients who completed 12 months in OLE ( N = 151), numerical improvements in effectiveness outcomes were seen in the PBO‐FFA group ( n = 59) after initiating fenfluramine and were similar to those in the FFA‐FFA group ( n = 92). Regression to the mean was not observed in the PBO‐FFA group, suggesting that changes were due to fenfluramine. Incidence of the most commonly reported treatment‐emergent adverse events increased in the PBO‐FFA group after fenfluramine initiation but decreased in the FFA‐FFA group in OLE. These data demonstrate rapid improvement in seizure frequency and global functioning in both groups with continued clinical improvement as the mean fenfluramine dose was increased. These results confirm that sustained fenfluramine treatment is effective and tolerable. Plain Language Summary This study assessed the change over time in the number of seizures, overall improvement, and side effects in patients with LGS receiving placebo (no active medicine) or fenfluramine in a 14‐week study; all patients later received fenfluramine in the extension study. Overall, the number of seizures (associated with a fall) decreased once patients initially receiving placebo changed to fenfluramine (optimal effect around Month 4 while receiving a higher dose), but as expected, common side effects were reported more frequently once patients began fenfluramine treatment. Patients, parents, and doctors should be aware of this time course to allow fenfluramine enough time to work.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Necker Enfants Malades Hospital, APHP, Member of the European Reference Network (ERN) EpiCARE, Reference Centre for Rare Epilepsies, Paris, France.
- Institut Imagine, U 1163, Paris, France.
- Université Paris Cité, Paris, France.
- Comprehensive Epilepsy Center NYU Langone Medical Center, New York, New York, USA.
- University of Leuven, Leuven, Belgium.
- Leuven Childhood Epilepsy Center, Leuven Brain Institute, UZ Leuven, Member of the ERN EpiCARE, Leuven, Belgium.
ORCID-Profile: Rima Nabbout, Orrin Devinsky, Lieven Lagae, Ingrid E Scheffer, Renzo Guerrini, Joseph Sullivan, Antonio Gil-Nagel, Sameer M Zuberi, Kate Riney, Amélie Lothe, Kelly G Knupp
Zitieren
APA
Nabbout, R., Devinsky, O., Lagae, L., Scheffer, I. E., Guerrini, R., Sullivan, J., Gil-Nagel, A., Zuberi, S. M., Riney, K., Healy, P., Abraham, J., Roper, R. Z., Langlois, M., Lothe, A., & Knupp, K. G. (2026). Changes in effectiveness and safety in patients with Lennox–Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open‐label extension study. Epilepsia Open. https://doi.org/10.1002/epi4.70320
Vancouver
Nabbout R, Devinsky O, Lagae L, Scheffer IE, Guerrini R, Sullivan J, et al. Changes in effectiveness and safety in patients with Lennox–Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open‐label extension study. Epilepsia Open. 2026. doi:10.1002/epi4.70320
BibTeX
@article{Nabbout2026,
author = {Nabbout, Rima and Devinsky, Orrin and Lagae, Lieven and Scheffer, Ingrid E and Guerrini, Renzo and Sullivan, Joseph and Gil-Nagel, Antonio and Zuberi, Sameer M and Riney, Kate and Healy, Patrick and Abraham, Jayne and Roper, Rebecca Zhang and Langlois, Mélanie and Lothe, Amélie and Knupp, Kelly G},
title = {Changes in effectiveness and safety in patients with Lennox–Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open‐label extension study},
journal = {Epilepsia Open},
year = {2026},
doi = {10.1002/epi4.70320}
}
EUVIMED